A vs ALB Stock Comparison

Scores Breakdown

Metric	A	ALB
📈 Growth	26/30	27/30
💰 Profitability	17/20	15/20
🏦 Financial Health	15/20	18/20
💵 Valuation	16/20	14/20
⚠️ Risk (lower is better)	5/10	7/10
Overall Score	79/100	77/100

Side-by-Side Summaries

A Analysis	ALB Analysis
📈 Growth & Financial Trajectory Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility. 💰 Margins & Cash Flow Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity. 🛡️ Balance Sheet & Liquidity Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure. ⚠️ Key Drivers & Risks Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption. Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.	📈 Growth & Financial Trajectory Across eight quarters, ALBEMARLE shows modest revenue growth from about $1.43B in 2024-Q2 to $1.74B in 2026-Q2, a gain of ~22%. Net income evolved from a loss of about -$176.6M to a positive $499.2M in 2026-Q2, with a mid-2025 dip, then a clear recovery into 2026. 💰 Margins & Cash Flow Gross margin expanded from a negative figure in 2024-Q2 to roughly 35% in 2025-Q1 and remained around the high 30% into 2026. Operating leverage benefited from higher margin production in later quarters. Net cash flow from operating activities, continuing, stayed strong, with $709.997M in 2026-Q2 and positive quarterly cash generation overall. Free cash flow was primarily consumed by investing activities, which were negative but the company still reported a positive overall cash flow in 2026-Q2. 🛡️ Balance Sheet & Liquidity Total assets of about $15.9B and equity of ~$10.5B support a solid balance sheet. Current assets of roughly $3.9B and current liabilities of $1.89B yield a healthy current ratio around 2.1x. Long-term debt remains moderate at about $1.88B, keeping balance-sheet risk contained. ⚠️ Key Drivers & Risks Drivers: Lithium/alloy battery demand; EV and energy-storage deployment Risks: commodity-price cyclicality; execution/valuation sensitivity to macro conditions

A Analysis

ALB Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

Across eight quarters, ALBEMARLE shows modest revenue growth from about $1.43B in 2024-Q2 to $1.74B in 2026-Q2, a gain of ~22%. Net income evolved from a loss of about -$176.6M to a positive $499.2M in 2026-Q2, with a mid-2025 dip, then a clear recovery into 2026.

💰 Margins & Cash Flow

Gross margin expanded from a negative figure in 2024-Q2 to roughly 35% in 2025-Q1 and remained around the high 30% into 2026. Operating leverage benefited from higher margin production in later quarters. Net cash flow from operating activities, continuing, stayed strong, with $709.997M in 2026-Q2 and positive quarterly cash generation overall. Free cash flow was primarily consumed by investing activities, which were negative but the company still reported a positive overall cash flow in 2026-Q2.

🛡️ Balance Sheet & Liquidity

Total assets of about $15.9B and equity of ~$10.5B support a solid balance sheet. Current assets of roughly $3.9B and current liabilities of $1.89B yield a healthy current ratio around 2.1x. Long-term debt remains moderate at about $1.88B, keeping balance-sheet risk contained.

⚠️ Key Drivers & Risks

Drivers: Lithium/alloy battery demand; EV and energy-storage deployment
Risks: commodity-price cyclicality; execution/valuation sensitivity to macro conditions

Similar Companies

AMAT Score: 79 AME Score: 78 ANET Score: 85 GOOGL Score: 80 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"